lomitapide + simvastatin

**lomitapide + simvastatin** is a combination therapy involving lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin). Lomitapide acts by inhibiting MTP, thereby reducing the assembly and secretion of apoB-containing lipoproteins (such as VLDL and LDL), primarily indicated for homozygous familial hypercholesterolemia. Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, reducing LDL cholesterol and overall cardiovascular risk. Co-administration increases simvastatin exposure via CYP3A4 inhibition by lomitapide, necessitating dose reductions to minimize myopathy and rhabdomyolysis risk[1][2].

Other names

lomitapide + simvastatin